Commentary: Oncologic drugs in patients with organ dysfunction: a summary

Area of Science:

• Oncology
• Pharmacology
• Nephrology
• Hepatology

Background:

• Limited prospective data exist on chemotherapy pharmacokinetics and toxicity in cancer patients with organ dysfunction.
• Current dosing guidelines for established chemotherapeutics in patients with renal or hepatic dysfunction are largely empiric.
• Increasing research focuses on newer agents, but established treatments require clearer guidance.

Purpose of the Study:

• To review existing data on the impact of renal and hepatic dysfunction on chemotherapy toxicity.
• To summarize current knowledge regarding chemotherapy dosing adjustments in patients with organ dysfunction.
• To provide a practical guide for clinicians managing cancer patients with compromised kidney or liver function.

Main Methods:

• Comprehensive literature review of prospective studies and case reports.
• Analysis of pharmacokinetic and clinical toxicity data for commonly used chemotherapeutics.
• Synthesis of information to address dosing and toxicity in renal and hepatic dysfunction.

Main Results:

• Significant variability exists in how renal and hepatic dysfunction affect the toxicity and pharmacokinetics of different chemotherapeutics.
• Case studies and limited prospective data highlight potential risks and the need for dose modification.
• Established agents often lack robust data, leading to reliance on empiric dose adjustments.

Conclusions:

• There is a critical need for more prospective studies to establish evidence-based dosing guidelines for chemotherapeutics in organ-impaired cancer patients.
• Clinicians should exercise caution and consider dose adjustments based on available data and patient-specific factors.
• This review provides a practical summary to aid in the management of chemotherapy in this complex patient population.